Prostate Brachytherapy With Cs-131: Long-term Results Compared With Published Stereotactic Body Radiotherapy Data.

IF 1.6 4区医学 Q4 ONCOLOGY

American Journal of Clinical Oncology-Cancer Clinical Trials Pub Date : 2025-01-01 Epub Date: 2024-10-17 DOI:10.1097/COC.0000000000001145

Ryan P Smith, Mohammed A Mohammed, Sushil Beriwal, Ronald M Benoit

{"title":"Prostate Brachytherapy With Cs-131: Long-term Results Compared With Published Stereotactic Body Radiotherapy Data.","authors":"Ryan P Smith, Mohammed A Mohammed, Sushil Beriwal, Ronald M Benoit","doi":"10.1097/COC.0000000000001145","DOIUrl":null,"url":null,"abstract":"Objective: We sought to compare our results of patients treated with Cs-131 prostate brachytherapy (PB) as monotherapy to recently published results of patients treated with stereotactic body radiotherapy.Methods: We analyzed data from patients treated at our institution with Cs-131 PB as monotherapy who had at least 5 years of follow-up and who prospectively completed expanded prostate cancer index composite questionnaires at baseline, 1 year, 2 years, and 5 years. We compared our data with the recently published data from radiation therapy oncology group (RTOG) 0938 and PACE-B (NCT01584258).Results: A total of 138 patients were included in our cohort. Using RTOG 0938's definition, the frequency of a decline in urinary function in our PB cohort was 43% compared with 41.3% in RTOG 0938. According to PACE-B's definition, our PB cohort had minimal clinically important differences in the urinary incontinence domain of 26.4% and in the urinary obstructive/irritative domain of 40.7% at 2 years compared with PACE-B's reported rate of 32% and 33%, respectively. The frequency of a >5-point change in the expanded prostate cancer index composite bowel summary score at 5 years was 25% compared with 30.7% in RTOG 0938. Our bowel difference at 2 years was 23% compared with PACE-B's reported 24%. Our 5-year biochemical disease free survival (bDFS) was 97.8%, compared with 91.3% in RTOG 0938 and 95.8% in PACE-B.Conclusions: Low dose rate (LDR) PB with Cs-131 as monotherapy provides excellent biochemical control of prostate cancer in low and intermediate-risk patients. Our cohort of patients had modest differences in patient-reported urinary and bowel quality of life compared with baseline. These differences were comparable to recently published stereotactic body radiotherapy data. When comparing prostate cancer treatments in terms of patient convenience and available resources, PB certainly should be considered.","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":"48 1","pages":"34-37"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology-Cancer Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000001145","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We sought to compare our results of patients treated with Cs-131 prostate brachytherapy (PB) as monotherapy to recently published results of patients treated with stereotactic body radiotherapy.

Methods: We analyzed data from patients treated at our institution with Cs-131 PB as monotherapy who had at least 5 years of follow-up and who prospectively completed expanded prostate cancer index composite questionnaires at baseline, 1 year, 2 years, and 5 years. We compared our data with the recently published data from radiation therapy oncology group (RTOG) 0938 and PACE-B (NCT01584258).

Results: A total of 138 patients were included in our cohort. Using RTOG 0938's definition, the frequency of a decline in urinary function in our PB cohort was 43% compared with 41.3% in RTOG 0938. According to PACE-B's definition, our PB cohort had minimal clinically important differences in the urinary incontinence domain of 26.4% and in the urinary obstructive/irritative domain of 40.7% at 2 years compared with PACE-B's reported rate of 32% and 33%, respectively. The frequency of a >5-point change in the expanded prostate cancer index composite bowel summary score at 5 years was 25% compared with 30.7% in RTOG 0938. Our bowel difference at 2 years was 23% compared with PACE-B's reported 24%. Our 5-year biochemical disease free survival (bDFS) was 97.8%, compared with 91.3% in RTOG 0938 and 95.8% in PACE-B.

Conclusions: Low dose rate (LDR) PB with Cs-131 as monotherapy provides excellent biochemical control of prostate cancer in low and intermediate-risk patients. Our cohort of patients had modest differences in patient-reported urinary and bowel quality of life compared with baseline. These differences were comparable to recently published stereotactic body radiotherapy data. When comparing prostate cancer treatments in terms of patient convenience and available resources, PB certainly should be considered.

查看原文本刊更多论文

前列腺近距离放射治疗Cs-131：与已发表的立体定向放射治疗数据比较的长期结果。

目的：我们试图将Cs-131前列腺近距离放射治疗（PB）作为单一治疗的患者的结果与最近发表的立体定向放射治疗的患者的结果进行比较。方法：我们分析了在我院接受Cs-131 PB单药治疗的患者的数据，这些患者至少进行了5年的随访，并在基线、1年、2年和5年完成了前列腺癌指数扩展复合问卷调查。我们将我们的数据与最近发表的放射治疗肿瘤组（RTOG） 0938和PACE-B （NCT01584258）的数据进行了比较。结果：我们的队列共纳入138例患者。根据RTOG 0938的定义，我们的PB队列中尿功能下降的频率为43%，而RTOG 0938为41.3%。根据PACE-B的定义，我们的PB队列在2年时尿失禁领域（26.4%）和尿阻塞/刺激领域（40.7%）的临床重要差异很小，而PACE-B报道的比例分别为32%和33%。5年前列腺癌扩展指数复合肠综合评分>5点变化的频率为25%，而RTOG 0938为30.7%。我们的2年肠道差异为23%，而PACE-B报告的差异为24%。我们的5年生化无病生存率（bDFS）为97.8%，而RTOG 0938为91.3%，PACE-B为95.8%。结论：低剂量率（LDR） PB联合Cs-131单药治疗低、中危前列腺癌患者具有良好的生化控制效果。与基线相比，我们的患者队列在患者报告的泌尿和肠道生活质量方面存在适度差异。这些差异与最近发表的立体定向放射治疗数据相当。在比较前列腺癌治疗的便利性和可用资源时，PB当然应该被考虑在内。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Clinical Oncology-Cancer Clinical Trials 医学-肿瘤学

CiteScore

4.90

自引率

0.00%

发文量

130

审稿时长

4-8 weeks

期刊介绍： American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists. The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles. The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.